Compass Financial Management
NKTR icon

Compass Financial Management’s Nektar Therapeutics NKTR Stock Holding History

Compass Financial Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$61 Hold
1
– – ﹤0.01% 1704
2026
Q2 		$73 Buy
+1
New +$73 ﹤0.01% 1516

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Compass Financial Management's NKTR Position: Q3 2026 in Review

Compass Financial Management held its Nektar Therapeutics (NKTR) position steady in Q3 2026 at 1 share worth $61. The position accounts for ﹤0.01% of the portfolio, ranked #1704.

Compass Financial Management first reported a position in NKTR in Q2 2026 and has held it in 2 quarters since. The position peaked at $73 in Q2 2026. 168 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • Compass Financial Management held 1 share of Nektar Therapeutics worth $61 as of Q3 2026.
  • Compass Financial Management left its Nektar Therapeutics share count unchanged in Q3 2026.
  • Nektar Therapeutics made up ﹤0.01% of Compass Financial Management's portfolio in Q3 2026, its #1704 holding.
  • Compass Financial Management first reported a position in Nektar Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Compass Financial Management's Nektar Therapeutics position peaked at $73 in Q2 2026.
  • 168 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on Compass Financial Management's 13F filing for Q3 2026, filed 30 Oct 2026.